| Carol Reid, MD | |
|
2200 Crow Ln, Myrtle Beach, SC 29577-1663 | |
| (843) 652-8390 | |
| Not Available |
| Full Name | Carol Reid |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 39 Years |
| Location | 2200 Crow Ln, Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508974361 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tidelands Waccamaw Community Hospital | Murrells inlet, SC | Hospital |
| Tidelands Georgetown Memorial Hospital | Georgetown, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Georgetown Physician Associates, Llc | 2365697398 | 149 |
| Waccamaw Community Hospital | 9133036932 | 80 |
News Archive
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
'Pilots' with physical impairments, who control computer avatars with their thoughts, will demonstrate how far brain-computer interface research has come as they compete in live events at CYBATHLON.
A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.
Embryonic stem cells with identical genomes grow into distinctive tissues, such as heart, bone, and brain. At one time, scientists believed the differences among cell types arose from various sets of genes switched on inside developing cells.
› Verified 4 days ago
| Entity Name | Georgetown Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982604021 PECOS PAC ID: 8224942123 Enrollment ID: O20031114000600 |
News Archive
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
'Pilots' with physical impairments, who control computer avatars with their thoughts, will demonstrate how far brain-computer interface research has come as they compete in live events at CYBATHLON.
A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.
Embryonic stem cells with identical genomes grow into distinctive tissues, such as heart, bone, and brain. At one time, scientists believed the differences among cell types arose from various sets of genes switched on inside developing cells.
› Verified 4 days ago
| Entity Name | Waccamaw Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972503910 PECOS PAC ID: 9133036932 Enrollment ID: O20031126000386 |
News Archive
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
'Pilots' with physical impairments, who control computer avatars with their thoughts, will demonstrate how far brain-computer interface research has come as they compete in live events at CYBATHLON.
A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.
Embryonic stem cells with identical genomes grow into distinctive tissues, such as heart, bone, and brain. At one time, scientists believed the differences among cell types arose from various sets of genes switched on inside developing cells.
› Verified 4 days ago
| Entity Name | Georgetown Physician Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235475930 PECOS PAC ID: 2365697398 Enrollment ID: O20130225000067 |
News Archive
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
'Pilots' with physical impairments, who control computer avatars with their thoughts, will demonstrate how far brain-computer interface research has come as they compete in live events at CYBATHLON.
A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.
Embryonic stem cells with identical genomes grow into distinctive tissues, such as heart, bone, and brain. At one time, scientists believed the differences among cell types arose from various sets of genes switched on inside developing cells.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carol Reid, MD Po Box 421718, Georgetown, SC 29442-4203 Ph: (843) 652-8226 | Carol Reid, MD 2200 Crow Ln, Myrtle Beach, SC 29577-1663 Ph: (843) 652-8390 |
News Archive
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
'Pilots' with physical impairments, who control computer avatars with their thoughts, will demonstrate how far brain-computer interface research has come as they compete in live events at CYBATHLON.
A study published online Oct. 18 in the Journal of the National Cancer Institute provides some new but qualified support for the idea that the immune system's response to allergies may reduce the risk of developing deadly brain tumors.
Embryonic stem cells with identical genomes grow into distinctive tissues, such as heart, bone, and brain. At one time, scientists believed the differences among cell types arose from various sets of genes switched on inside developing cells.
› Verified 4 days ago
Dr. Sheila Putman, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1021 Cipriana Dr Ste 220, Myrtle Beach, SC 29572 Phone: 843-449-6449 | |
Mr. Daniel L Rosner, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 915 Medical Circle, Myrtle Beach, SC 29572 Phone: 843-449-6449 Fax: 843-449-1069 | |
Mr. Calhoun D Cunningham, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1021 Cipriana Dr, Ste 220, Myrtle Beach, SC 29572 Phone: 843-449-6449 Fax: 843-449-1069 | |
Mr. Richard C Osman, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 915 Medical Circle, Myrtle Beach, SC 29572 Phone: 843-449-6449 Fax: 843-449-1069 |